Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Abbott infectious news

Four pharmacy chains and one pharmaceutical wholesaler filed a class action suit against ABT alleging the pharma unlawfully raised the price of Norvir ritonavir to restrict competition in the boosted protease inhibitor market. The HIV

Read the full 358 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE